Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

Taipei, Taiwan and Harrow, England, February 11, 2019 – An exclusive license agreement for the commercialisation of Foresee Pharmaceutical’s (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare.

Read More


The Falsified Medicines Directive – Sandra Lee’s interview published in Pharmacy Business – February 2019 edition

Sandra Lee, Managing Director of Operations, explains why FMD is important and how the industry is preparing.

Read More


Accord Fawdon celebrates its one year anniversary

The team at Accord Fawdon recently celebrated the factory’s one-year anniversary with cakes and reflections on the successes of the past year.

Read More


Accord and other leading voices in the pharmaceutical and financial industry debate how to drive consistent and long-term growth

In November 2018, at the House of Lords, Accord partnered Generics bulletin to bring influential

Read More


Accord UK leading the conversation on how biosimilars can improve access to effective cancer treatments

Cancer is one of the biggest global healthcare challenges facing clinicians today. The rising cost of treatments can affect patients’ access to affordable, effective treatments.

Accord Healthcare is dedicated to improving the lives of patients, both in the UK and across the world, through their generics and biosimilar portfolio.  Accord have been engaging with healthcare professionals and NHS commissioners at two key events to start the conversation on the role that biosimilars can play in increasing access to effective, affordable cancer medicines.

Read More


Accord Healthcare are proud supporters of IHP

Millions of people around the world are suffering because they have little or no access to medicine and health care. They live in communities made vulnerable by conflict, displacement or natural disasters.

The main focus of International Health Partners (IHP) is to stop the suffering caused by poor access to medicine; they help people in hard-to-reach, vulnerable and disaster-hit communities get better access to medicine by overseeing, coordinating and delivering strategic medical product donations.

Read More


Accord acts differently to plot a path towards further growth

James Burt, EVP EMENA and Paul Tredwell, VP Specialty Brands met with Aidan Fry from Generics Bulletin to talk about Accord’s continued rise across Europe in hospital and retail generics and their exciting new developments in added-value products, including biosimilars.

Read More


Accord Healthcare - the most recognised company at the Global Generics & Biosimilar Awards 2018

We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year.  As well, Intas & Accord Healthcare also picked up the award for Company of the Year Asia-Pacific.

Read More


UK generic medicine price flux? – the real data behind the headlines

In 2017, the UK generic medicines market experienced an uncharacteristic amount of volatility creating a number of headlines in the pharmacy trade and mainstream media around the pricing and supply of generic medicines. 

Read More

Media Contact:

For all Accord news and media contact information please contact [email protected]